Gossamer Bio, Inc. (GOSS)

Gossamer Bio’s investment case remains centered on seralutinib, after the company submitted a New Drug Application (NDA) for pulmonary arterial hypertension (PAH). The Phase 3 PROSERA miss creates regulatory uncertainty, while contingent financing could provide substantial capital if the U.S. Food and Drug Administration accepts or approves the application. GOSS was down 2.90% in the regular session on November 2, 2026.